SCHEMBL21708016

SCHEMBL21708016

Cc1ccc2nc(-c3ccc(O)cc3)cn2c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 14/20 0.80
RAB9A P51151 13/20 0.80
KDM4E B2RXH2 11/20 0.80
ALDH1A1 P00352 11/20 0.80
SMN1; SMN2 Q16637 9/20 0.80
PAX8 Q06710 2/20 0.80
KMT2A Q03164 2/20 0.80
MEN1 O00255 1/20 0.80
MITF O75030 1/20 0.80
KDM5A P29375 1/20 0.80
KDM5C P41229 1/20 0.80
APP P05067 3/20 0.71
HPGD P15428 6/20 0.68
PKM P14618 4/20 0.68
GFER P55789 3/20 0.68
POLB P06746 3/20 0.68
TP53 P04637 2/20 0.68
HSD17B10 Q99714 2/20 0.68
L3MBTL1 Q9Y468 2/20 0.68
TSHR P16473 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396368 0.89 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2257095 0.87 APP (0.73) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2194530 0.83 NPC1 (0.70) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL973527 0.83 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1691890 0.83 ALDH1A3 (0.82) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1983316 0.83 NPC1 (0.80) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1691254 0.83 NPC1 (0.80) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL13325747 0.83 NPC1 (0.90) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL10120370 0.83 NPC1 (0.80) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1691247 0.83 NPC1 (0.80) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A NPC1 4209/4885RAB9A 3350/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.